These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15701872)

  • 1. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
    Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
    Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH
    Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT).
    Francis RJ; Mather SJ; Chester K; Sharma SK; Bhatia J; Pedley RB; Waibel R; Green AJ; Begent RH
    Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1090-6. PubMed ID: 15029458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
    Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
    Webley SD; Francis RJ; Pedley RB; Sharma SK; Begent RH; Hartley JA; Hochhauser D
    Br J Cancer; 2001 Jun; 84(12):1671-6. PubMed ID: 11401322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
    Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH
    Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
    Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
    Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy.
    Kogelberg H; Tolner B; Sharma SK; Lowdell MW; Qureshi U; Robson M; Hillyer T; Pedley RB; Vervecken W; Contreras R; Begent RH; Chester KA
    Glycobiology; 2007 Jan; 17(1):36-45. PubMed ID: 17000699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein.
    Michael NP; Chester KA; Melton RG; Robson L; Nicholas W; Boden JA; Pedley RB; Begent RH; Sherwood RF; Minton NP
    Immunotechnology; 1996 Feb; 2(1):47-57. PubMed ID: 9373327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
    Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
    Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
    Springer CJ; Niculescu-Duvaz I
    Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
    Schepelmann S; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Chen P; Marais R; Springer CJ
    Cancer Res; 2007 May; 67(10):4949-55. PubMed ID: 17510425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT).
    Mayer A; Sharma SK; Tolner B; Minton NP; Purdy D; Amlot P; Tharakan G; Begent RH; Chester KA
    Br J Cancer; 2004 Jun; 90(12):2402-10. PubMed ID: 15162148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).
    Alderson RF; Toki BE; Roberge M; Geng W; Basler J; Chin R; Liu A; Ueda R; Hodges D; Escandon E; Chen T; Kanavarioti T; Babé L; Senter PD; Fox JA; Schellenberger V
    Bioconjug Chem; 2006; 17(2):410-8. PubMed ID: 16536473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
    Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
    Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.
    Coelho V; Dernedde J; Petrausch U; Panjideh H; Fuchs H; Menzel C; Dübel S; Keilholz U; Thiel E; Deckert PM
    Int J Oncol; 2007 Oct; 31(4):951-7. PubMed ID: 17786329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer.
    Panjideh H; Da Silva Coelho VC; Dernedde J; Bachran C; Förster GJ; Franke J; Fasold P; Fuchs H; Thiel E; Deckert PM
    Int J Oncol; 2008 Apr; 32(4):925-30. PubMed ID: 18360720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.